A DNA topoisomerase I inhibitor 5 mg


≥98% pure A DNA topoisomerase I inhibitor 5 mg



(±)16(17)-DiHDPA is produced from cytochrome P450 epoxygenase action on docosahexaenoic acid (DHA; Item No. 90310). It has been shown to inhibit VEGF-induced angiogenesis and reduce cancer cell metastasis in mice.1 (±)16(17)-DiHDPA MaxSpec® standard is a quantitative grade standard of (±)16(17)-DiHDPA (Item No. 18176) that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This (±)16(17)-DiHDPA MaxSpec® standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.WARNING This product is not for human or veterinary use.


There are no reviews yet.

Be the first to review “A DNA topoisomerase I inhibitor 5 mg”

Your email address will not be published.

Got something to discuss?


Add to cart